X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ABBOTT INDIA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ABBOTT INDIA IPCA LABS/
ABBOTT INDIA
 
P/E (TTM) x 29.1 36.7 79.4% View Chart
P/BV x 3.7 9.4 39.3% View Chart
Dividend Yield % 0.1 0.7 17.3%  

Financials

 IPCA LABS   ABBOTT INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ABBOTT INDIA
Mar-18
IPCA LABS/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs6956,110 11.4%   
Low Rs4003,996 10.0%   
Sales per share (Unadj.) Rs260.21,552.2 16.8%  
Earnings per share (Unadj.) Rs19.0188.8 10.0%  
Cash flow per share (Unadj.) Rs33.1196.4 16.8%  
Dividends per share (Unadj.) Rs1.0055.00 1.8%  
Dividend yield (eoy) %0.21.1 16.8%  
Book value per share (Unadj.) Rs213.0796.6 26.7%  
Shares outstanding (eoy) m126.2021.25 593.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.13.3 64.7%   
Avg P/E ratio x28.926.8 107.9%  
P/CF ratio (eoy) x16.625.7 64.4%  
Price / Book Value ratio x2.66.3 40.5%  
Dividend payout %5.329.1 18.1%   
Avg Mkt Cap Rs m69,120107,376 64.4%   
No. of employees `00013.33.3 399.0%   
Total wages/salary Rs m7,3593,937 186.9%   
Avg. sales/employee Rs Th2,477.49,929.3 25.0%   
Avg. wages/employee Rs Th555.21,185.1 46.8%   
Avg. net profit/employee Rs Th180.61,207.7 15.0%   
INCOME DATA
Net Sales Rs m32,83632,985 99.5%  
Other income Rs m4181,170 35.7%   
Total revenues Rs m33,25434,155 97.4%   
Gross profit Rs m4,5055,245 85.9%  
Depreciation Rs m1,777162 1,097.8%   
Interest Rs m24038 628.8%   
Profit before tax Rs m2,9056,215 46.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5112,203 23.2%   
Profit after tax Rs m2,3944,012 59.7%  
Gross profit margin %13.715.9 86.3%  
Effective tax rate %17.635.4 49.6%   
Net profit margin %7.312.2 59.9%  
BALANCE SHEET DATA
Current assets Rs m19,45522,655 85.9%   
Current liabilities Rs m10,0766,681 150.8%   
Net working cap to sales %28.648.4 59.0%  
Current ratio x1.93.4 56.9%  
Inventory Days Days9865 151.1%  
Debtors Days Days6729 229.7%  
Net fixed assets Rs m20,260835 2,424.9%   
Share capital Rs m252213 118.8%   
"Free" reserves Rs m26,63316,715 159.3%   
Net worth Rs m26,88616,928 158.8%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17324,162 170.4%  
Interest coverage x13.1163.7 8.0%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.4 58.4%   
Return on assets %6.416.8 38.2%  
Return on equity %8.923.7 37.6%  
Return on capital %10.836.9 29.1%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,642369 4,244.3%   
Fx outflow Rs m4,8843,807 128.3%   
Net fx Rs m10,759-3,438 -312.9%   
CASH FLOW
From Operations Rs m3,4111,527 223.4%  
From Investments Rs m-1,354-2,148 63.0%  
From Financial Activity Rs m-1,304-1,024 127.3%  
Net Cashflow Rs m753-1,646 -45.8%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 7.9 144.3%  
FIIs % 25.3 0.1 25,300.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.1 101.8%  
Shareholders   36,892 18,270 201.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare IPCA LABS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Dec 12, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - LUPIN LTD COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS